Glioblastoma

New CHM 1101 (CLXT CAR T) multi-center clinical trial activated at Sarah Cannon Research Institute (SCRI) in Austin, TexasEnrolment now open to patients with recurrent and/or progressive glioblastoma multiforme (GBM), the most common and…

<!-- Name:DistributionId Value:1000797728 --> <!-- Name:NewsArchiveTags Value:Partnerships,Research --> <!-- Name:NewsArchiveOrgTags…